ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
36 hedge funds and large institutions have $103M invested in ESSA Pharma in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 4 closing their positions.
15% more capital invested
Capital invested by funds: $89.8M → $103M (+$13.6M)
0.48% more ownership
Funds ownership: 75.41% → 75.89% (+0.48%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
8% less funds holding
Funds holding: 39 → 36 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
83% less call options, than puts
Call options by funds: $27K | Put options by funds: $159K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$901K |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$245K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$133K |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$39.4K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$30.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$229K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$168K |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$76.4K |
| 4 |
Two Sigma Advisers
New York
|
-$73.2K |
| 5 |
State Street
Boston,
Massachusetts
|
-$65.9K |
EPIX Hedge Fund Activity: Q3 2023 in Review
36 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q3 2023, worth a combined $103M — up 15% from $89.8M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EPIX and 1 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was Morgan Stanley, adding an estimated $901K. The largest seller was OrbiMed, cutting an estimated $229K.
- 36 institutional investors held ESSA Pharma (EPIX) as of Q3 2023, down from 39 in Q2 2023.
- Funds reported $103M of ESSA Pharma stock for Q3 2023, up 15% quarter-over-quarter.
- 1 fund opened new ESSA Pharma positions in Q3 2023 and 4 closed out, a net change of -3 holders.
- The largest ESSA Pharma buyer in Q3 2023 was Morgan Stanley, an estimated $901K added.
- The largest ESSA Pharma seller in Q3 2023 was OrbiMed, an estimated $229K sold.
Based on aggregated 13F filings for Q3 2023.